Abstract
Various immunomodulating agents have been tried for the treatment of steroid-resistant focal segmental glomerulosclerosis (FSGS) in the native kidney. A few case series and small studies have reported mixed results with the use of Rituximab for this indication. We report on the case of a 76-year-old male with steroid-resistant FSGS successfully treated with rituximab and remained in remission at the end of six months. A review of the literature highlights the paucity of data on this subject. We conclude that rituximab is a potentially useful treatment for steroid resistant FSGS and larger controlled studies are needed to further define its role in this setting.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1175-1179 |
| Number of pages | 5 |
| Journal | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. |
| Volume | 28 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 Sept 2017 |
| Externally published | Yes |
Fingerprint
Dive into the research topics of 'Treatment of steroid-resistant focal segmental glomerulosclerosis with rituximab: A case report and review of literature'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver